Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine vs Remifentanil for Sedation in Septic Shock
NCT05551910Unknown
- Sponsor
- The First Hospital of Jilin University
- Start
- Jan 2023
- Primary completion
- Jan 2025
01
Overview
Randomised trial of esketamine in septic shock (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Norepinephrine dosage at 2 years. Status: unknown.
02
Drugs
esketamine
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05551910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551910.